Home > Cardiology > ACC 2019 > Vascular Medicine > Clopidogrel monotherapy after 1-month DAPT may be beneficial in stent patients

Clopidogrel monotherapy after 1-month DAPT may be beneficial in stent patients

Conference
ACC 2019
Trial
STOPDAPT-2

Outcomes of the STOPDAPT-2 trial show that 1 month of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy offers a net clinical benefit when it comes to ischaemic and bleeding events in comparison with 12 months of DAPT consisting of aspirin and clopidogrel after the implantation of cobalt-chromium everolimus-eluting stents [1].

STOPDAPT-2 was a Japanese study involving 89 centres and >3,000 patients. A total of 38% of these patients had acute coronary syndrome. Patients received DAPT for the first month (clopidogrel or prasugrel and aspirin); after that period, they were randomised to clopidogrel monotherapy or DAPT (clopidogrel and aspirin) through 1 year. The primary endpoint of the study was a composite of cardiovascular (CV) death, myocardial infarction (MI), definite stent thrombosis, stroke, or thrombolysis in myocardial infarction major/minor bleeding at 12 months.

The results suggested clopidogrel monotherapy was superio...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on